<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02789644</url>
  </required_header>
  <id_info>
    <org_study_id>UDCA_elderly</org_study_id>
    <nct_id>NCT02789644</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Investigate Pharmacokinetics, Metabolomics and Biomarker in Elderly After UDCA Administration</brief_title>
  <official_title>A Randomized, Open-label Clinical Trial to Investigate Pharmacokinetics, Metabolomics and Biomarker in Healthy Elderly Subjects After Ursodeoxycholic Acid Administration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A clinical study to investigate pharmacokinetics, metabolomics and biomarker in healthy
      elderly subject after ursodeoxycholic acid administration
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study has a randomized, open-label, two-treatment, one-sequence, multiple drug
      administration design. The purpose of this study is as follows; To investigate
      pharmacokinetics, metabolomics and biomarker in healthy elderly subject after ursodeoxycholic
      acid administration
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve (AUC) of ursodeoxycholic acid</measure>
    <time_frame>predose and 2, 4, 5, 7, 9, 10, 12, 24h postdose</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Aged</condition>
  <arm_group>
    <arm_group_label>Ursodeoxycholic acid 400mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 1: Ursodeoxycholic acid 400mg qd Day 2 to 15: Ursodeoxycholic acid 200mg bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ursodeoxycholic acid 800mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 1: Ursodeoxycholic acid 800mg qd Day 2 to 15: Ursodeoxycholic acid 200mg bid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ursodeoxycholic Acid</intervention_name>
    <description>Day 1: Ursodeoxycholic acid 400mg or 800mg qd Day 2 to 15: Ursodeoxycholic acid 200mg bid</description>
    <arm_group_label>Ursodeoxycholic acid 400mg</arm_group_label>
    <arm_group_label>Ursodeoxycholic acid 800mg</arm_group_label>
    <other_name>Ursa tab.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Subjects aged 70 - 84 years

          -  A body mass index (BMI) in the range of 18.5 kg/m2 - 29.9 kg/m2.

          -  Good health based on complete medical history, physical examinations, vital signs,
             electrocardiography (ECG), and clinical laboratory evaluations.

        Exclusion Criteria:

          -  Subjects who have clinically significant disease of cardiovascular, respiratory,
             renal, endocrinological, hematological, gastrointestinal, neurological(central nervous
             system), psychiatric disorders or malignant tumor

          -  Subject judged not eligible for study participation by investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>84 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jae-Yong Chung, M.D., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Clinical Pharmacology and Therapeutics, Seoul National University Bundang hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jae-Yong Chung, M.D., Ph.D</last_name>
    <phone>+82-031-787-3955</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jae-Yong Chung, MD, PhD</last_name>
      <phone>+82-031-787-3955</phone>
    </contact>
    <investigator>
      <last_name>Jae-Yong Chung, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 31, 2016</study_first_submitted>
  <study_first_submitted_qc>May 31, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2016</study_first_posted>
  <last_update_submitted>May 31, 2016</last_update_submitted>
  <last_update_submitted_qc>May 31, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Jae Yong Chung</investigator_full_name>
    <investigator_title>M.D., Ph.D</investigator_title>
  </responsible_party>
  <keyword>Ursodeoxycholic acid</keyword>
  <keyword>Metabolomics/biomarker</keyword>
  <keyword>Pharmacokinetics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ursodeoxycholic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

